David Miles

14.7k citations

94 papers · 8.4k indexed · 4 hit papers · h-index 37

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
Radiology, Nuclear Medicine and Imaging top 0.2%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Oncology 78
- HER2/EGFR in Cancer Research 53
- Cancer Treatment and Pharmacology 29
- Peptidase Inhibition and Analysis 11
- Cancer Immunotherapy and Biomarkers 10
Radiology, Nuclear Medicine and Imaging 30
- Monoclonal and Polyclonal Antibodies Research 27

Co-authors: Luca Gianni Véronique Dièras José Baselga Manfred Welslau Ian E. Krop Mark D. Pegram Sunil Verma Ellie Guardino
Journals: Journal of Clinical Oncology (26 papers)Annals of Oncology (10 papers)Cancer Research (7 papers)British Journal of Cancer (4 papers)Breast Cancer Research (3 papers)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

David Miles

90 papers receiving 8.2k citations

Hit Papers

align trajectories log scale

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial 2017 · 465 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 The Lancet Oncology
2012 New England Journal of Medicine
2010 Journal of Clinical Oncology
2010 Journal of Clinical Oncology

Peers

Countries citing papers authored by David Miles

Since Specialization

Citations

This map shows the geographic impact of David Miles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Miles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Miles more than expected).

Fields of papers citing papers by David Miles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Miles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Miles. The network helps show where David Miles may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Miles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Miles Line = papers co-authored together David Miles links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data PubMed ·Helena Earl, Louise Hiller, Janet Dunn, Dong Young Kim, Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, Dora Hatzidaki, Vassilis Georgoulias, Jean Abraham, David Miles, David Cameron, Andrew Wardley, Xavier Pivot	2025	0
2	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone Radiology ·Michael Kosmin, Anwar R. Padhani, Andrew Gogbashian, David Woolf, Mei-Lin Ah-See, Peter Ostler, Stephanie Sutherland, David Miles, Jillian Noble, Dow‐Mu Koh, Andrea Marshall, Janet Dunn, Andreas Makris	2020	22
3	Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results BMC Cancer ·Louise Hiller, Janet Dunn, Shrushma Loi, Anne-Laure Vallier, Loes Hoebers, David Cameron, David Miles, Andrew Wardley, Helena Earl	2018	5
4	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma Molecular Cancer Therapeutics ·Aysegül Ilhan‐Mutlu, Matthias Osswald, Yunxiang Liao, Miriam Gömmel, Martin Reck, David Miles, Paola Mariani, Luca Gianni, Beatrix Lutiger, Aynur Butun Ayha, Stefanie Srock, Pablo Ernesto Pérez, Frits Thorsen, Louisa von Baumgarten, Matthias Preusser, Wolfgang Wick, Frank Winkler	2016	86
5	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation European Journal of Cancer ·David Miles, David Cameron, Igor Bondarenko, Werden in, Juan Carlos Alcedo, R.I. Lopez, Seock‐Ah Im, Jean‐Luc Canon, Yaroslav Shparyk, Denise A. Yardley, Norikazu Masuda, Jungsil Ro, Neelima Denduluri, Stanislas Hubeaux, Cheng S. Quah, Carlos Bais, Joyce O’Shaughnessy	2016	92
6	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA Annals of Oncology ·Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras	2014	286
7	Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer Cancer ·Manfred Welslau, Véronique Dièras, Joohyuk Sohn, Sara A. Hurvitz, Deepa Lalla, Fang Ting Liang, Betsy Althaus, Ellie Guardino, David Miles	2013	90
8	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) Breast Cancer Research and Treatment ·David Miles, José Baselga, Dino Amadori, Patrapim Sunpaweravong, Semiglazov Vf, Adam Knott, Emma Clark, Graham Ross, Sandra M. Swain	2013	43
9	Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study The Oncologist ·Sandra M. Swain, Michael S. Ewer, Javier Cortés, Dino Amadori, David Miles, Adam Knott, Emma Clark, Mark Benyunes, Graham Ross, José Baselga	2013	106
10	Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial Journal of Cancer ·Nuhad K. Ibrahim, James L. Murray, Dapeng Zhou, Elizabeth A. Mittendorf, Dory Sample, N. Galinskaja, David Miles	2013	61
11	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer New England Journal of Medicine ·Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell Hit paper breakdown →	2012	2665
12	Using bevacizumab to treat metastatic cancer: UK consensus guidelines British Journal of Hospital Medicine ·David Miles, John Bridgewater, Peter Ellis, Michael R. Harrison, Paul Nathan, Malcolm Nicolson, Sherif Raouf, Duncan Wheatley, Chris Plummer	2010	9
13	Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer Breast Cancer Research ·David Miles	2009	10
14	Molecular approach to breast cancer treatment Seminars in Oncology ·Yosef Yarden, José Baselga, David Miles	2004	63
15	Comparison of 'three weekly' (q3w) vs 'four weekly' (q4w) adjuvant CMF chemotherapy in operable breast cancer Breast Cancer Research and Treatment ·David Miles, K W Ryder, R.D. Rubens, Robert Leonard, David Cameron	2003	3
16	Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting Breast Cancer Research ·David Miles	2001	28
17	Breast Cancer and the Immune System: Opportunities and Pitfalls Journal of Mammary Gland Biology and Neoplasia ·T.A. Plunkett, I. Correa, David Miles, Joyce Taylor‐Papadimitriou	2001	8
18	Role of nitric oxide in tumour progression: Lessons from human tumours Cancer and Metastasis Reviews ·Lindy L. Thomsen, David Miles	1998	244
19	Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin‐2 European Journal of Clinical Investigation ·David Miles, H. Krewinkel, Frances R. Balkwill, P. Thavasu, Salvador Moncada	1994	21
20	Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Journal of Clinical Oncology ·David Miles, Tiruchelvarayan Rajendra, C. M. Ash, R.M. Rudd, C Trask, SG Spiro, Walter M. Gregory, Jonathan A. Ledermann, R L Souhami, Peter Harper	1994	40

About David Miles

David Miles is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 94 papers that have together received 8.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (53 papers), Cancer Treatment and Pharmacology (29 papers), Monoclonal and Polyclonal Antibodies Research (27 papers), Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (14 papers), Peptidase Inhibition and Analysis (11 papers), Immunotherapy and Immune Responses (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Oncology (6.0k citations), Radiology, Nuclear Medicine and Imaging (2.7k citations), Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (2.2k citations) and Genetics (543 citations). David Miles has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Luca Gianni, Véronique Dièras, José Baselga, Manfred Welslau, Ian E. Krop, Mark D. Pegram, Sunil Verma, Ellie Guardino, Kim T. Blackwell and Fang Ting Liang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, British Journal of Cancer and Breast Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact